Health Care·Biotechnology·$19.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -78.26% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.41 | N/A | -78.26% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced this quarter, particularly in managing expenses. They remain focused on their long-term strategy.
Management highlighted ongoing challenges in achieving profitability.
They emphasized their commitment to advancing their pipeline despite the EPS miss.
Roivant Sciences reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 5.11%, likely due to optimism about their ongoing projects and future potential. The lack of revenue data and guidance may leave investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FORTIS INC
Feb 11, 2022